Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
06/2003
06/12/2003WO2003047596A2 Ointment for soothing dermatitis
06/12/2003WO2003047593A1 Melanogenesis inhibitors and whitening agents comprising ergosterol derivatives and compositions containing ergosterol derivatives
06/12/2003WO2003047589A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047570A1 Benzazole derivatives for the treatment of scleroderma
06/12/2003WO2003047565A1 Melanogenesis inhibitors and whitening agents comprising egonol derivatives and compositions containing egonol derivatives
06/12/2003WO2003047554A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts
06/12/2003WO2003047535A1 External preparation for the skin and copolymer to be used therein
06/12/2003WO2003047533A2 Composition for treating the surface of the skin
06/12/2003WO2003047530A2 Storage-stable fibrin sealant
06/12/2003WO2003047516A2 Pyrimidine compounds
06/12/2003WO2003047497A1 Isotretinoin nanoparticulate compositions
06/12/2003WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof
06/12/2003WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions
06/12/2003WO2002078703A8 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003WO2002018544A3 Method and reagents for treatment of skin disorders by modulating the notch pathway
06/12/2003WO2001085096A9 Mast cell regulation
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109587 Gelling composition
06/12/2003US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol.
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109504 Inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109474 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109439 Keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163 in lower concentrations
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109434 One or more kidney tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expression such
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030108953 Truncated egf receptor
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108651 Therapeutic and anti-oxidant for variety of health purposes, including treatment of skin damage; also useful as a natural antibacterial, antiviral and fungicidal agricultural product
06/12/2003US20030108624 Treating micro- and macroangiopathic conditions with a bioflavonoid plant extract as antioxidant along with a neovascular controller as an angiogenesis inhibitor; vision defects; wound healing agents; cardiovascular disorders
06/12/2003US20030108620 Prophylactic treatment of secondary injury of tissue traumatic event, surgery, transplant, nonproliferative tissue, burns, using of 3-methylsulfonyl-4-piperidinyl benzoyl)guanidine methanesulfonate or N,N-dimethylamiloride
06/12/2003US20030108617 Use of a formulation made of or containing at least one dissimilated milk serum
06/12/2003US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar
06/12/2003US20030108593 Reduction inhibitory agent for active oxygen eliminating activity
06/12/2003US20030108577 Crosslinked polymer containing acrylamido-2-methyl-1-propanesulfonic acid
06/12/2003US20030108544 Compositions and methods for the diagnosis and treatment of tumor
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108510 Synergistic mixture of rutin, escin and bufemin; branching of arteries, veins
06/12/2003US20030108500 Hair growth stimulant compositions
06/12/2003US20030108496 Compositions comprising phenyl-glycine derivatives
06/12/2003US20030108493 Extracts from residues left in the production of wine
06/12/2003CA2819733A1 Use of selenite-containing compounds to be topically or buccally administered for treating or preventing sunburn
06/12/2003CA2819731A1 Use of selenite-containing compounds to be topically or buccally administered for treating an insect bite
06/12/2003CA2735287A1 Use of selenite-containing compounds to be topically or buccally administered
06/12/2003CA2473727A1 Storage-stable fibrin sealant
06/12/2003CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
06/12/2003CA2469134A1 Novel peptide and pharmaceutical use of the same
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468946A1 External preparation for the skin and copolymer to be used therein
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468525A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
06/12/2003CA2468349A1 Pyrimidine compounds
06/12/2003CA2466697A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/11/2003EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1317933A1 Preparations for coating wound
06/11/2003EP1317928A1 Wild apple polyphenol and process for producing the same
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317922A1 Antipyretic preparation containing xylitol
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317458A2 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2alpha antagonists
06/11/2003EP1317457A2 INTERHETEROARYL 7-OXABICYCLIC 2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F 2$g(a)? ANTAGONISTS
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors
06/11/2003EP1317425A2 Resorcinol derivatives
06/11/2003EP1317424A2 Polyamine analogues as therapeutic and diagnostic agents
06/11/2003EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317414A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3
06/11/2003EP1317310A1 Use of serum response factor (srf) modulator for treating srf related diseases
06/11/2003EP1317284A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
06/11/2003EP1317283A2 Tweak receptor agonists as anti-angiogenic agents
06/11/2003EP1317274A2 Peptide composition for treatment of periodontal diseases and prevention of skin aging
06/11/2003EP1317252A2 Pharmaceutical composition having specific water activity
06/11/2003EP1131065B1 Dialkylfumarates for the treatment of autoimmune diseases
06/11/2003EP1060161B1 Matrix metalloproteinase inhibitors
06/11/2003EP1039891A4 Treatment of scar tissue using lipoic acid
06/11/2003EP0973741B1 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist
06/11/2003EP0848755B1 Vegf-related protein
06/11/2003EP0750511B1 Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
06/11/2003CN1423700A Multifunctional polypeptides comprising a binding site to and epitope of the NKG2D receptor complex
06/11/2003CN1423695A Antisense oligonucleotides
06/11/2003CN1423646A Hetero cyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
1 ... 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 ... 1065